This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Piribedil is a dopamine agonist used with or without levodopa in the treatment of Parkinson's disease.
- Generic Name
- Piribedil
- DrugBank Accession Number
- DB12478
- Background
Piribedil has been investigated in Parkinson's Disease.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Piribedil (DB12478)
- Weight
- Average: 298.346
Monoisotopic: 298.142975836 - Chemical Formula
- C16H18N4O2
- Synonyms
- Piribedil
- External IDs
- ET-495
- EU-4200
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UDopamine D2 receptor Not Available Humans UDopamine D3 receptor Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetophenazine The therapeutic efficacy of Piribedil can be decreased when used in combination with Acetophenazine. Amisulpride The therapeutic efficacy of Piribedil can be decreased when used in combination with Amisulpride. Amoxapine The therapeutic efficacy of Piribedil can be decreased when used in combination with Amoxapine. Apomorphine The risk or severity of adverse effects can be decreased when Apomorphine is combined with Piribedil. Aripiprazole The risk or severity of adverse effects can be decreased when Aripiprazole is combined with Piribedil. Aripiprazole lauroxil The therapeutic efficacy of Piribedil can be decreased when used in combination with Aripiprazole lauroxil. Asenapine The therapeutic efficacy of Piribedil can be decreased when used in combination with Asenapine. Benperidol The therapeutic efficacy of Piribedil can be decreased when used in combination with Benperidol. Brexpiprazole The risk or severity of adverse effects can be decreased when Brexpiprazole is combined with Piribedil. Bromocriptine The risk or severity of adverse effects can be decreased when Bromocriptine is combined with Piribedil. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- ATC Codes
- N04BC08 — Piribedil
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Diazinanes
- Sub Class
- Piperazines
- Direct Parent
- N-arylpiperazines
- Alternative Parents
- Benzodioxoles / Dialkylarylamines / N-alkylpiperazines / Aralkylamines / Aminopyrimidines and derivatives / Benzenoids / Heteroaromatic compounds / Trialkylamines / Oxacyclic compounds / Azacyclic compounds show 3 more
- Substituents
- Acetal / Amine / Aminopyrimidine / Aralkylamine / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Benzodioxole / Dialkylarylamine / Heteroaromatic compound show 12 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- DO22K1PRDJ
- CAS number
- 3605-01-4
- InChI Key
- OQDPVLVUJFGPGQ-UHFFFAOYSA-N
- InChI
- InChI=1S/C16H18N4O2/c1-4-17-16(18-5-1)20-8-6-19(7-9-20)11-13-2-3-14-15(10-13)22-12-21-14/h1-5,10H,6-9,11-12H2
- IUPAC Name
- 2-{4-[(2H-1,3-benzodioxol-5-yl)methyl]piperazin-1-yl}pyrimidine
- SMILES
- C(N1CCN(CC1)C1=NC=CC=N1)C1=CC2=C(OCO2)C=C1
References
- General References
- External Links
- PubChem Compound
- 4850
- PubChem Substance
- 347828716
- ChemSpider
- 4684
- BindingDB
- 85092
- 8353
- ChEBI
- 92833
- ChEMBL
- CHEMBL1371770
- ZINC
- ZINC000019537374
- Wikipedia
- Piribedil
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Idiopathic Parkinson's Disease 1 Not Available Completed Not Available Parkinson's Disease (PD) 3 Not Available Completed Treatment Tinnitus 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet, coated Oral 50 mg Tablet, extended release Oral 50 mg Tablet, film coated, extended release Oral Tablet, film coated Oral 50 mg Tablet, coated Oral 20 MG Tablet, extended release Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 1.57 mg/mL ALOGPS logP 1.56 ALOGPS logP 2.03 Chemaxon logS -2.3 ALOGPS pKa (Strongest Basic) 6.53 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 50.72 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 83.53 m3·mol-1 Chemaxon Polarizability 31.87 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available MS/MS Spectrum - , positive LC-MS/MS splash10-000i-1930000000-45b06a981c7ebf1054da
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Potassium channel regulator activity
- Specific Function
- Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
- Gene Name
- DRD2
- Uniprot ID
- P14416
- Uniprot Name
- D(2) dopamine receptor
- Molecular Weight
- 50618.91 Da
References
- Millan MJ, Girardon S, Monneyron S, Dekeyne A: Discriminative stimulus properties of the dopamine D3 receptor agonists, PD128,907 and 7-OH-DPAT: a comparative characterization with novel ligands at D3 versus D2 receptors. Neuropharmacology. 2000 Feb 14;39(4):586-98. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- G-protein coupled amine receptor activity
- Specific Function
- Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
- Gene Name
- DRD3
- Uniprot ID
- P35462
- Uniprot Name
- D(3) dopamine receptor
- Molecular Weight
- 44224.335 Da
References
- Millan MJ, Girardon S, Monneyron S, Dekeyne A: Discriminative stimulus properties of the dopamine D3 receptor agonists, PD128,907 and 7-OH-DPAT: a comparative characterization with novel ligands at D3 versus D2 receptors. Neuropharmacology. 2000 Feb 14;39(4):586-98. [Article]
Drug created at October 20, 2016 22:32 / Updated at May 29, 2021 18:11